| Revenue growth | 23.6% YoY revenue growth; crossed ₹1,000cr quarterly revenue mark. |
|---|---|
| Margins | Temporary 150bps hit due to GTM investments; recovery by H2FY27. |
| Demand visibility | Strong; 5-8% industry CAGR through 2028 with GenAI tailwinds. |
| Management confidence | High; shifted from 'cautiously optimistic' to 'excited and confident'. |
Growth
Revenue grew 23.6% YoY in INR terms (18.2% USD), driven by strategic deepening with Top-20 pharma and scaling mid-market clients.
Outlook
Management expects EBITDA margin recovery in H2FY27 as aggressive AI and GTM investments are fully absorbed.
Risks
₹20.3cr provision for a US class-action lawsuit and significant forex volatility charges impact near-term bottom-line quality.
Earnings Call filed with NSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹608.95
- Market cap
- ₹14,670 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.6×Sector 57.8×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Earnings Call Transcript: Key Takeaways
Indegene delivered its strongest Q1 growth in four years, yet remains burdened by elevated costs from strategic investments and workforce transformation.
Indegene Investor Presentation: Key Takeaways
Indegene reported Q1'FY27 revenue of ₹10,631M (+39.7% YoY) with an EBITDA margin of 16.9%. The strategy focuses on scaling GenAI-powered solutions and deepening engagement with large pharma.
Indegene Q1 FY27 Results: Net Profit ₹116.2 Cr, Down 0.2% YoY
Indegene Ltd reported revenue from operations of ₹1,063 Cr (+39.7% YoY) and net profit of ₹116.2 Cr (-0.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹116.2 Cr · -0.2% YoY
Indegene Earnings Call: Key Takeaways
Indegene reported FY26 revenue of INR 35,105M with 19.4% adjusted EBITDA margin, positioning itself as an AI-embedded specialist displacing traditional agencies and CROs in life sciences.